Facebook Twitter LinkedIn Google Plus RSS

Merck completes $4B purchase of Idenix

By ,
Merck completed its deal for Idenix Pharmaceuticals on Tuesday.
Merck completed its deal for Idenix Pharmaceuticals on Tuesday. - ()

Merck announced Tuesday that it has completed its multibillion-dollar tender offer for Idenix Pharmaceuticals, Inc.

The Whitehouse Station-based drugmaker said approximately 82.5 percent of Idenix shares were tendered at the purchase price of $24.50 per share. That means Merck will be able to formally complete the acquisition of the Massachusetts-based company Tuesday.

RELATED: Merck to acquire Mass. pharma company for nearly $4B

RELATED: Merck begins tender offer to acquire Idenix for $4B

The purchase price values Idenix at approximately $3.85 billion.

Upon completion of the deal, Idenix will become a wholly owned subsidiary of Merck, and its common stock will no longer be traded.

ALSO ON NJBIZ:

Two top Roseland executives to leave Mack-Cali

Hartz sells Secaucus office building for $69M

Onyx signs leases with Sony Music, two others

You May Have Missed...

Write to the Editorial Department at editorial@njbiz.com

Leave a Comment

test

Please note: All comments will be reviewed and may take up to 24 hours to appear on the site.

Post Comment
View Comment Policy

Comments

close